Contemporary Myocarditis: Diagnostic Challenges and Management Strategies

A Grand Rounds Review for the Practicing Internist and Trainee

Dr Neeraj Manikath

1. The Case That Should Keep You Up at Night

A 24-year-old software engineer walks into casualty with two days of "flu" — myalgia, low-grade fever, and now a vague retrosternal heaviness he describes as "tightness, not really pain." His ECG shows diffuse, saddle-shaped ST elevation with PR depression. The resident signs him out as "viral pericarditis, reassure and discharge on ibuprofen." Six hours later he is found collapsed in the hospital toilet, in pulseless electrical activity. He is resuscitated, but transthoracic echocardiography now shows an ejection fraction of 20% with a globally hypokinetic, non-dilated left ventricle. Troponin, which was never sent on the first visit, comes back at 42 times the upper limit of normal.

This is not a rare, exotic diagnosis. It is myocarditis presenting exactly the way it usually presents — quietly, mimicking something more benign, in a young and otherwise healthy patient — right up until it doesn't.

Why this matters now, more than ever:

🩺 Epidemiological hook: Myocarditis is now recognized as a leading cause of sudden cardiac death in people under 35, accounting for up to 12% of such deaths in some autopsy series, and it is estimated to cause 1.5 million new cases worldwide annually. Yet clinically apparent myocarditis is believed to represent only a small fraction of the true burden — most cases are subclinical, and many fulminant presentations are diagnosed only at autopsy.

Three forces have converged over the last five years to make this an unusually active — and unusually confusing — area of internal medicine:

Immune checkpoint inhibitors (ICIs) have moved from niche oncology drugs to first-line therapy across a dozen cancers, bringing with them a rare but ferociously lethal form of fulminant lymphocytic myocarditis with reported mortality historically as high as 25–50%.
mRNA COVID-19 vaccination produced a well-characterized, usually self-limited, myopericarditis syndrome in young males — a "natural experiment" that sharpened our understanding of how mild, biopsy-negative-but-CMR-positive myocarditis behaves.
The 2024 ACC Expert Consensus Decision Pathway and the landmark 2025 ESC Guidelines for the Management of Myocarditis and Pericarditis — the first-ever joint ESC guideline unifying these two conditions — have fundamentally rewritten how we diagnose, risk-stratify, and treat this disease. If your mental model of myocarditis dates from your residency textbook, it is out of date.

This review distills what has changed, what has not, and — most importantly — what you actually need to do differently at the bedside on Monday morning.

2. Pathophysiology — Only What Changes Your Management

You do not need a paragraph on cytokine cascades to manage this patient well. You need to understand three phases, because each phase has a different treatment implication.

Phase 1 — Viral/triggered injury (Days 0–3). A cardiotropic insult — most often parvovirus B19, HHV-6, enterovirus/coxsackievirus, or now, non-infectious triggers like ICI-driven autoreactive T-cells or vaccine-associated innate immune activation — causes direct myocyte injury. Clinical implication: antiviral therapy has essentially no proven role here for common viral myocarditis; by the time patients present, active viral replication has usually already been cleared by the innate immune system.

Phase 2 — Autoimmune amplification (Days 4–14). This is the phase that actually destroys myocardium. T-cell-mediated and, in some phenotypes, antibody-mediated autoimmunity against cardiac self-antigens (often molecular mimicry with viral epitopes) drives ongoing myocyte necrosis and interstitial edema/fibrosis. Clinical implication: this is the window in which immunosuppression — when indicated — has biological plausibility, and it is why timing of endomyocardial biopsy (EMB) matters so much (see Section 7).

Phase 3 — Remodeling/chronic inflammatory cardiomyopathy. In a subset of patients, ongoing low-grade inflammation drives fibrofatty replacement, chamber dilation, and an arrhythmogenic substrate — the entity the new 2025 ESC guideline formally renames inflammatory cardiomyopathy, defined as chronic myocarditis with cardiac dysfunction and remodeling. Clinical implication: this is the phenotype that needs guideline-directed medical therapy (GDMT) for heart failure, an implantable defibrillator risk conversation, and — in genetically susceptible patients — cascade family screening, because a meaningful fraction of "chronic myocarditis" turns out to be a genetic arrhythmogenic cardiomyopathy unmasked by an inflammatory trigger.

🪙 Pearl: The single biggest conceptual shift in the 2025 ESC guideline is the move away from myocarditis as a single snapshot diagnosis and toward a disease continuum — acute myocarditis → resolution or chronic/relapsing inflammatory myopericardial syndrome → inflammatory cardiomyopathy. Ask yourself at every follow-up visit not "does this patient still have myocarditis?" but "which stage of the continuum is this patient in today?"

3. Clinical Pearls 🪙 — Bedside Truths That Aren't in the Textbook

🪙 Pearl 1 — The chest pain is often not the chief complaint that gets recognized. Patients frequently present with what sounds like a musculoskeletal or gastro-esophageal complaint — "tightness when I take a deep breath," "a burning after eating." A recent flu-like illness within the preceding 1–4 weeks, in a patient under 50 with atypical chest discomfort, should trigger a troponin and ECG before you reach for antacids or NSAIDs.

🪙 Pearl 2 — Troponin can be normal, especially in chronic/relapsing disease. In the acute fulminant phase troponin is almost always elevated, but in subacute or chronic inflammatory cardiomyopathy, troponin is frequently normal or only intermittently elevated because active myonecrosis has slowed even as inflammation and remodeling continue. A normal troponin does not exclude chronic inflammatory cardiomyopathy in a patient with new unexplained heart failure or ventricular arrhythmia.

🪙 Pearl 3 — Beware the "normal" ECG. A completely normal ECG is reassuring but does not rule out myocarditis; sensitivity of ECG abnormalities is only around 50%. Conversely, the combination of sinus tachycardia that is disproportionate to fever plus even minor, nonspecific ST-T changes in a young patient with a viral prodrome should raise your index of suspicion rather than lower it.

🪙 Pearl 4 — Fulminant myocarditis paradoxically has the best long-term prognosis if the patient survives the acute phase. This is one of the most counterintuitive and clinically important facts in the field. Patients who present in cardiogenic shock or with malignant arrhythmia (fulminant phenotype) but survive to discharge tend to have near-complete recovery of ejection fraction at long-term follow-up, in contrast to patients with a more indolent, "acute non-fulminant" presentation, who paradoxically have higher rates of progression to dilated cardiomyopathy. The lesson: aggressive hemodynamic support (including early mechanical circulatory support) in the sickest patients is not futile — it is precisely these patients who, if they survive, recover best.

🪙 Pearl 5 — Sinus tachycardia out of proportion to everything else is a red flag, not a nuisance vital sign. In an inpatient with viral symptoms and a heart rate that will not settle despite antipyretics and adequate volume status, think myocarditis before you think "anxiety" or "deconditioning."

4. Oysters 🦪 — The Hidden Gems Most Clinicians Miss

🦪 Oyster 1 — Eosinophilic myocarditis and DRESS. Any patient started on a new drug (especially anticonvulsants, allopurinol, or antibiotics) in the preceding 2–6 weeks who develops myocarditis with peripheral eosinophilia should be worked up for a hypersensitivity/DRESS-related eosinophilic myocarditis. This variant responds dramatically to corticosteroids and the causative drug must be permanently withdrawn — missing this diagnosis and treating it as "just viral myocarditis" denies the patient a highly treatable, steroid-responsive condition.

🦪 Oyster 2 — Giant cell myocarditis hides behind heart block. New-onset, unexplained high-grade AV block or ventricular tachycardia in a middle-aged adult, especially with a background of another autoimmune disease (thymoma, myasthenia gravis, inflammatory bowel disease), should prompt urgent consideration of giant cell myocarditis (GCM) — a rapidly progressive, often fatal disease if untreated, but one in which combination immunosuppression (corticosteroids plus a calcineurin inhibitor, with or without a T-cell antibody) dramatically improves transplant-free survival. GCM is a biopsy-or-die diagnosis: this is one of the few situations in myocarditis where EMB genuinely changes management within days.

🦪 Oyster 3 — Cardiac sarcoidosis masquerading as "idiopathic" chronic myocarditis/cardiomyopathy. Any patient labeled with unexplained non-ischemic cardiomyopathy plus conduction disease (especially heart block in a patient under 60) deserves a chest CT/hilar lymph node review and, where feasible, cardiac PET or CMR looking for patchy, patchy-basal-septal late gadolinium enhancement and FDG uptake. Sarcoidosis is a treatable mimic that is easy to lump into "burnt-out myocarditis" if you don't specifically look for it.

🦪 Oyster 4 — The post-viral "recovery" visit is where relapse is missed. A substantial minority of patients who look clinically well at 1–3 months have persistent late gadolinium enhancement or edema on repeat CMR — a marker associated with higher long-term arrhythmic risk even when the ejection fraction has normalized. Discharging a patient from follow-up purely on the basis of a normalized echo, without a follow-up CMR at 3–6 months in moderate-to-severe presentations, is a common and consequential oversight.

🦪 Oyster 5 — Athletes are a special population, and the return-to-play decision is a medicolegal minefield. Even mild, subclinical myocarditis diagnosed incidentally (e.g., during post-COVID cardiac screening) mandates a minimum 3–6 month exercise restriction with reassessment of biomarkers, rhythm (ambulatory monitoring), and ventricular function/CMR before clearance — because exercise during active myocardial inflammation is a recognized precipitant of malignant arrhythmia and sudden death in this population.

5. Clinical Hacks & Tips ⚡ — Shortcuts the Masters Actually Use

⚡ Hack 1 — Use the "chest pain + fresh troponin rise + normal (or near-normal) coronaries" triad as your mental trigger for CMR, not just cath lab clearance. Too often, once the angiogram is clean, the patient is labeled "MINOCA, discharge with reassurance" and the myocarditis workup stops there. Flip the sequence in your head: a clean angiogram in a patient with an troponin-positive ACS-mimicking presentation should activate, not terminate, your myocarditis workup.

⚡ Hack 2 — Order CRP and ESR even though they won't make the diagnosis. They are nonspecific, but a strikingly elevated CRP in a young patient with chest pain and a clean coronary angiogram is a useful "second data point" that nudges you toward requesting CMR sooner rather than watching and waiting.

⚡ Hack 3 — Learn to read (or at least request specifically) the updated Lake Louise Criteria on CMR reports. The updated criteria require evidence of both myocardial edema (T2-based criterion: regional/global T2 signal increase or elevated T2 mapping values) and non-ischemic myocardial injury (T1-based criterion: elevated native T1/ECV, or late gadolinium enhancement in a non-coronary distribution). Ancillary criteria (pericardial effusion, systolic dysfunction) support but do not replace these two pillars. If your radiology report doesn't explicitly address both T1- and T2-based criteria, ask for it — a report that just says "consistent with myocarditis" without stating which criteria were met is not good enough for a diagnosis that will shape months of management.

⚡ Hack 4 — Risk-stratify before you decide whether biopsy is needed, not after. Use a simple mental checklist: (a) hemodynamic instability or cardiogenic shock, (b) sustained ventricular arrhythmia or high-grade AV block, (c) rapidly deteriorating LV function despite supportive therapy, or (d) suspected giant cell myocarditis/cardiac sarcoidosis/eosinophilic myocarditis based on clinical clues above. Any one of these tips the balance firmly toward early EMB, because each represents a scenario where a specific, biopsy-confirmed diagnosis changes therapy immediately.

⚡ Hack 5 — For suspected ICI-myocarditis, treat the clock as your enemy. Do not wait for a "confirmatory" biopsy before starting high-dose corticosteroids if the clinical suspicion is even moderate (rising troponin plus new ECG change or arrhythmia in a patient on an ICI). Mortality in this entity is driven by delay; start pulse methylprednisolone empirically, hold the ICI, and biopsy/EMB findings can follow rather than lead the first dose of steroid.

⚡ Hack 6 — Screen for concomitant myositis/myasthenic crisis in every ICI-myocarditis patient. ICI myocarditis frequently co-occurs with immune-related myositis and myasthenia-like neuromuscular junction disease, and the combination markedly raises the risk of respiratory failure. Check a CK, and have a low threshold for pulmonary function testing / negative inspiratory force in these patients — this is the single biggest reason the field has moved toward early ICU-level monitoring for suspected ICI-myocarditis.

6. State-of-the-Art Updates — What Has Actually Changed Practice

1. The unified 2025 ESC Guidelines on Myocarditis and Pericarditis. For the first time, ESC has issued a single integrated guideline covering both conditions under the umbrella term "inflammatory myopericardial syndrome," reflecting how often they overlap clinically. The guideline introduces staged disease definitions, formalizes inflammatory cardiomyopathy as a distinct downstream entity, and provides structured diagnostic algorithms specific to three clinical presentations: acute chest pain, acute heart failure, and new arrhythmia.

2. The 2024 ACC Expert Consensus Decision Pathway (ECDP). This US-based document complements the ESC guideline with a practical, algorithmic approach for American practice, emphasizing a high index of suspicion in patients with chest pain, arrhythmia, or heart failure following a viral illness, autoimmune disease flare, or cardiotoxin exposure, and providing structured criteria for when EMB adds diagnostic/prognostic value that outweighs procedural risk.

3. Updated Lake Louise Criteria and mapping techniques. Native T1 and T2 mapping (quantitative, less operator-dependent than older qualitative sequences) has become the diagnostic backbone of non-invasive myocarditis diagnosis, with sensitivity now approaching that of biopsy in appropriately selected patients — reducing (though not eliminating) the need for invasive tissue sampling in stable patients.

4. The Seaport histopathological grading criteria for EMB. A quantitative, reproducible grading framework for endomyocardial biopsy has renewed clinical interest in biopsy, moving it beyond the older, poorly reproducible Dallas criteria and improving prognostic stratification when biopsy is performed.

5. Combination immunomodulation for ICI-myocarditis. Building on early single-agent abatacept data, current evidence supports early combination therapy with abatacept plus the JAK inhibitor ruxolitinib on top of corticosteroids for severe/steroid-refractory ICI-myocarditis, with observational data suggesting a dramatic reduction in mortality compared with corticosteroids plus later, sequential second-line agents. Randomized confirmation (the ATRIUM trial) is ongoing, but the observational signal has already shifted practice at experienced centers toward earlier, combined immunosuppression rather than a slow "step-up" ladder.

6. Mechanistic and precision therapies on the horizon. Interleukin-1 inhibition (anakinra), colchicine, and other mechanism-targeted immunomodulators are under active investigation for acute and relapsing myocarditis/pericarditis, building on the established efficacy of these agents in idiopathic recurrent pericarditis.

7. mRNA vaccine-associated myocarditis — reassuring long-term data. Large cohort follow-up of predominantly young male patients with mRNA COVID-19 vaccine-associated myopericarditis has shown that the overwhelming majority have a mild clinical course with rapid symptomatic and biomarker recovery, though a meaningful minority retain subtle CMR abnormalities at follow-up, reinforcing the importance of structured follow-up imaging rather than presuming complete resolution from clinical recovery alone.

7. Diagnostic Nuances — Separating Good from Great

History — the questions residents forget to ask:

Exact timeline of viral prodrome relative to cardiac symptoms (autoimmune-phase myocarditis classically lags the viral illness by 1–3 weeks).
Complete drug history over the preceding 8 weeks, explicitly including over-the-counter, herbal, and recreational substances (cocaine and amphetamines cause a distinct catecholaminergic/hypersensitivity myocarditis).
Full oncology history and exact ICI regimen/cycle number — myocarditis risk is highest in the first 3 months of therapy and with combination CTLA-4/PD-1 blockade.
Family history of sudden cardiac death or cardiomyopathy — because an inflammatory trigger can unmask an underlying genetic arrhythmogenic cardiomyopathy, and this changes the long-term surveillance plan for the whole family.

Examination pearls:

A new S3 gallop or a friction rub in a young patient with chest pain and fever is far more specific for myopericarditis than either finding alone.
Look specifically for signs that point away from myocarditis and toward a mimic: asymmetric limb pulses/blood pressures (aortic dissection), a pleuritic component worsened by lying flat and eased by sitting forward (isolated pericarditis), or focal wall-motion territory findings on bedside echo (still favors ischemia until proven otherwise).

Investigations — the sequencing that matters:

ECG and high-sensitivity troponin in every patient with the clinical triad (chest pain/dyspnea/palpitations + recent viral illness + no clear alternative explanation).
Transthoracic echocardiography early — not primarily to diagnose myocarditis (it cannot), but to exclude a regional wall motion abnormality pointing to true ischemia, quantify LV function, and screen for a pericardial effusion/tamponade physiology that needs urgent action.
Coronary evaluation (invasive angiography or CT coronary angiography depending on pretest probability and age) whenever the presentation could plausibly be ischemic — myocarditis is, in significant part, a diagnosis of exclusion in the acute chest-pain pathway.
CMR is the pivotal non-invasive test once ischemia is reasonably excluded, ideally performed within the first 2–3 weeks of symptom onset, when sensitivity for edema is highest.
EMB reserved for the specific high-value scenarios in Hack 4 above — not a routine test for every troponin-positive, CMR-positive patient with a benign trajectory.

🪙 Diagnostic pearl: CMR performed too early (within 48–72 hours) or too late (beyond 3–4 weeks) can be falsely reassuring, because acute edema signal takes some hours to develop and resolves over subsequent weeks. If your index CMR is negative but clinical suspicion remains high, repeat it — do not abandon the diagnosis on the strength of a single, poorly timed scan.

8. Management Intricacies — Drugs, Doses, Timing, and Pitfalls

General supportive care (applies to essentially all patients):

Bed rest / restriction from vigorous exercise for a minimum of 3–6 months, reassessed with biomarkers, rhythm monitoring, and imaging before clearance — this single, unglamorous intervention is arguably the highest-yield "treatment" in mild-to-moderate disease.
Standard GDMT (ACE-inhibitor/ARB or ARNI, beta-blocker once hemodynamically tolerated, mineralocorticoid receptor antagonist, SGLT2 inhibitor) for any patient with reduced ejection fraction, exactly as you would for any other cause of heart failure with reduced EF — myocarditis does not exempt a patient from evidence-based heart failure therapy.
Avoid NSAIDs in patients with significant LV systolic dysfunction (they can worsen fluid retention and afterload); they remain reasonable for isolated pericarditis-predominant presentations with preserved LV function.
Colchicine has an established role in reducing pericarditis recurrence in the myopericarditis-predominant phenotype and is increasingly used as adjunctive therapy.

Immunosuppression — who, when, how:

Idiopathic lymphocytic myocarditis without a specific treatable cause: immunosuppression is not routinely recommended based on current evidence; supportive/GDMT-based management remains the default.
Giant cell myocarditis: combination immunosuppression (high-dose corticosteroids plus a calcineurin inhibitor such as cyclosporine, often with anti-thymocyte globulin or another T-cell-directed agent) started promptly once biopsy-confirmed, continued for an extended taper, with early referral to an advanced heart failure/transplant center given the risk of rapid deterioration.
Eosinophilic/hypersensitivity myocarditis: withdraw the offending drug immediately; high-dose corticosteroids produce a typically rapid and dramatic response.
Cardiac sarcoidosis: corticosteroids as first-line immunosuppression, with steroid-sparing agents (methotrexate, mycophenolate, or biologic therapy) for relapsing or steroid-refractory disease, alongside arrhythmia-specific management (device therapy is frequently required given the conduction disease burden).
ICI-associated myocarditis: hold the ICI; start pulse-dose intravenous methylprednisolone (typically 500–1000 mg/day for 3–5 days) without waiting for biopsy confirmation if clinical suspicion is moderate-to-high; escalate early to combination second-line immunosuppression (abatacept plus ruxolitinib is the emerging evidence-based combination) for severe, steroid-refractory, or rapidly progressive disease rather than a slow sequential step-up — the data now favor early combination over "wait and see if steroids alone work."

Arrhythmia management pitfalls:

Avoid reflexive permanent pacemaker/ICD implantation in the acute phase for AV block or ventricular arrhythmia — a meaningful proportion of conduction disease in acute myocarditis is reversible as inflammation resolves, and a wearable cardioverter-defibrillator is a useful bridging strategy while allowing time for recovery before committing to a permanent device.
In giant cell myocarditis and cardiac sarcoidosis, by contrast, the arrhythmic substrate is often fixed/fibrotic, and device therapy decisions should not be deferred on the assumption of spontaneous recovery.

Mechanical circulatory support:

In fulminant myocarditis with cardiogenic shock, do not delay escalation to temporary mechanical circulatory support (intra-aortic balloon pump, percutaneous ventricular assist device, or veno-arterial ECMO) while "waiting to see" — early institution, before end-organ hypoperfusion sets in, is associated with better recovery, and (per Pearl 4) these are precisely the patients most likely to recover fully if they survive the acute insult.

🪙 Management pearl: Resist the urge to start a beta-blocker at full dose on day one in a patient with acute myocarditis and borderline hemodynamics — negative inotropy during active myocardial inflammation can precipitate decompensation. Start low, go slow, and uptitrate as the acute inflammatory phase settles, exactly as you would in any fresh, hemodynamically fragile new heart failure presentation.

9. When to Escalate, When to Watch — Decision Thresholds

Admit and monitor closely (telemetry-capable bed, minimum):

Any elevated troponin with ECG change, arrhythmia, or even mild LV dysfunction.
Any patient on active ICI therapy with a rising troponin, irrespective of symptom severity — this population deteriorates fast and unpredictably.

Escalate to ICU / advanced cardiac care:

Hemodynamic instability, sustained ventricular arrhythmia, or high-grade AV block.
Rapidly worsening LV function on serial echocardiography despite supportive measures.
Any ICI-myocarditis patient with concomitant myositis/neuromuscular involvement — because respiratory failure can be abrupt.

Refer for endomyocardial biopsy (cardiology/advanced heart failure input):

Any of the "red flag" criteria in Hack 4 (Section 5) — instability, malignant arrhythmia/high-grade block, rapid deterioration despite treatment, or suspected giant cell myocarditis/eosinophilic myocarditis/sarcoidosis.

Refer to advanced heart failure/transplant center:

Suspected or confirmed giant cell myocarditis (mortality without treatment is extremely high; even with treatment, this is a disease best managed where mechanical circulatory support and transplantation are immediately available).
Cardiogenic shock not responding to first-line supportive measures — early referral, before the patient is peri-arrest, dramatically changes options and outcomes.

Safe to watch as an outpatient (with structured follow-up):

Mild, hemodynamically stable, biomarker-limited disease with preserved LV function, no arrhythmia, and no red-flag features — provided a clear follow-up plan (clinical review, biomarkers, and repeat imaging at 3–6 months, exercise restriction counseling) is documented before discharge.

🪙 Escalation pearl: The decision to escalate should be driven far more by trajectory than by any single value. A troponin that is falling on serial measurement in a hemodynamically stable patient is reassuring even if the peak was very high; a troponin that is rising, even modestly, in a patient who "looks fine" is not.

10. Summary Table and Memory Aid

Mnemonic — Remember myocarditis with "M-Y-O-C-A-R-D-I-T-I-S":

Letter	Reminds you to...
M	Mimics of ACS — always exclude coronary disease first in the chest-pain presentation
Y	Young patients + viral prodrome = raise your index of suspicion
O	Oyster diagnoses — eosinophilic, giant cell, sarcoid — actively look for treatable subtypes
C	CMR is the pivotal non-invasive test; time it right (2–3 weeks post-onset)
A	Avoid NSAIDs if LV dysfunction present; avoid early full-dose beta-blockade
R	Red flags (shock, malignant arrhythmia, high-grade block, rapid deterioration) mandate biopsy/ICU
D	Drugs and toxins — always take a meticulous 8-week exposure history
I	ICI myocarditis — hold the drug, start steroids early, escalate to combination immunosuppression fast
T	Trajectory, not a single value, drives escalation decisions
I	Inflammatory cardiomyopathy — the chronic downstream phenotype needing GDMT + genetic/family screening
S	Sport/exercise restriction for 3–6 months with re-imaging before clearance

Quick-reference summary table

Domain	Key Point
Best initial non-invasive test	Cardiac MRI (updated Lake Louise criteria: T1- and T2-based evidence)
When biopsy is essential	Shock, malignant arrhythmia/high-grade AV block, rapid deterioration, suspected giant cell/eosinophilic/sarcoid myocarditis
Best long-term prognosis	Paradoxically, fulminant presentations who survive the acute phase
First-line therapy, idiopathic lymphocytic myocarditis	Supportive care + standard heart failure GDMT; routine immunosuppression not recommended
First-line therapy, ICI-myocarditis	Hold ICI + early pulse corticosteroids; escalate early to abatacept + ruxolitinib if severe/refractory
Steroid-responsive "don't miss" mimic	Eosinophilic/hypersensitivity (drug-induced) myocarditis
Exercise restriction	Minimum 3–6 months, reassess before clearance
New unifying concept (2025 ESC)	Inflammatory myopericardial syndrome → inflammatory cardiomyopathy as chronic phenotype

11. References (Vancouver Style)

Schulz-Menger J, Collini V, Gröschel J, Adler Y, Brucato A, Caforio ALP, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J. 2025;46(41):3952-4041.
Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, et al. 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;84(25):2628-2661.
Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158-3176.
Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Allenbach Y, et al. Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100-1115.
Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377-2379.
Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.
Puzzo L, Amico F, Sciacca A, Vecchio GM, Caltabiano R, Ardiri A, et al. Advances in management of complicated myocarditis and inflammatory cardiomyopathy. Curr Treat Options Cardiovasc Med. 2026;28(1):15.
Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020;13(11):e007405.
Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2019;74(3):299-311.
Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56(14):1071-1078.
Kytö V, Sipilä J, Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681-1684.
Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e579-e646.
Cooper LT Jr, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the AHA, ACC, and ESC. Circulation. 2007;116(19):2216-2233.
Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: a review. JAMA. 2023;329(13):1098-1113.
Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132-2139.

This review reflects evidence and guideline updates available as of mid-2026, including the 2025 ESC integrated myocarditis/pericarditis guideline and the 2024 ACC expert consensus decision pathway. As with all rapidly evolving fields, clinicians should verify drug doses and evolving trial data (e.g., the ongoing ATRIUM abatacept trial) against current local protocols before applying them to individual patients.

learningmedicine

Sunday, August 23, 2026